Clinical pharmacology of intraperitoneal cisplatin-based chemotherapy.
The management of intraperitoneal tumors, especially when confined to the peritoneal cavity and/or associated with malignant ascites, requires the use of intraperitoneal (i.p.) cisplatin-based chemotherapy. This therapeutic approach, enabling high concentrations of drug and long duration of tumor tissue exposure, while generating a systemic exposure similar to that obtained with intravenous (i.v.) infusion, significantly improves therapeutic ratio. Nowadays, as feasibility issues are easy to overcome, intraperitoneal chemotherapy provides a safe, effective treatment for the management of peritoneal disease, particularly ovarian carcinoma. In this paper we review pharmacological issues of intraperitoneal cisplatin-based chemotherapy in order to provide a ready to use information collection for clinical practice and ongoing research.
Conti
M
M
Istituto Oncologico Romagnolo - Laboratory of Clinical Pharmacology and Toxicology, "Santa Maria delle Croci" Hospital, Ravenna, Italy. ra.hotossicologia@ausl.ra.it
De Giorgi
U
U
Tazzari
V
V
Bezzi
F
F
Baccini
C
C
D002945:Cisplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D006979:Hyperthermia, Induced; D007274:Injections, Intraperitoneal; D010534:Peritoneal Neoplasms / Q000188:drug therapy*
D002945:Cisplatin